Nature Biotechnology

• 

  Publication Venue For

  • Increasing the specificity of CRISPR systems with engineered RNA secondary structures. 2019
  • Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass..  36:606-613. 2018
  • The NIEHS TaRGET II Consortium and environmental epigenomics..  36:225-227. 2018
  • Functional interrogation and mining of natively paired human VH:VL antibody repertoires..  36:152-155. 2018
  • Programmable assembly of pressure sensors using pattern-forming bacteria..  35:1087-1093. 2017
  • CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome..  35:561-568. 2017
  • In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis..  35:569-576. 2017
  • A recellularized human colon model identifies cancer driver genes..  34:845-851. 2016
  • Cas9 loosens its grip on off-target sites..  34:298-299. 2016
  • COMPASS identifies T-cell subsets correlated with clinical outcomes..  33:610-616. 2015
  • Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting..  33:656-660. 2015
  • Generation of articular chondrocytes from human pluripotent stem cells..  33:638-645. 2015
  • Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers..  33:510-517. 2015
  • Erratum: Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis (Nature Biotechnology (2012) 30 (1217-1224)).  31:565. 2013
  • Heterogeneity of tumor-induced gene expression changes in the human metabolic network..  31:522-529. 2013
  • Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis..  30:1217-1224. 2012
  • Hybrid error correction and de novo assembly of single-molecule sequencing reads..  30:693-700. 2012
  • Erratum: Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India (Nature Biotechnology (2010) 28 (671-678)).  30:193. 2012
  • Verification of systems biology research in the age of collaborative competition..  29:811-815. 2011
  • Letter to editor.  28:1243. 2010
  • GREAT improves functional interpretation of cis-regulatory regions..  28:495-501. 2010
  • Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle..  28:79-82. 2010
  • Cancer's insatiable appetite..  27:916-917. 2009
  • Sensitive digital quantification of DNA methylation in clinical samples..  27:858-863. 2009
  • Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors..  27:839-849. 2009
  • Proteomic analysis of S-nitrosylation and denitrosylation by resin-assisted capture..  27:557-559. 2009
  • In need of a reality check.  27:422-422. 2009
  • A kernel for the Tropical Disease Initiative..  27:320-321. 2009
  • Erratum: Proprietary science, open science and the role of patent disclosure: The case of zinc-finger proteins (Nature Biotechnology (2009) 27 (140-144)).  27:485-. 2009
  • Fungal bioinsecticide with a sting..  25:1367-1368. 2007
  • Folate fortification of rice by metabolic engineering..  25:1277-1279. 2007
  • The metabolomics standards initiative..  25:846-848. 2007
  • Oversight of US genetic testing laboratories..  24:1083-1090. 2006
  • Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras..  24:1005-1015. 2006
  • AAV does the shuffle..  24:158-160. 2006
  • Life, diversity and the pursuit of haplotypes..  23:1376-1377. 2005
  • Islets for all?.  23:1231-1232. 2005
  • Reverse engineering gene regulatory networks..  23:554-555. 2005
  • Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity..  23:344-348. 2005
  • Antidote-mediated control of an anticoagulant aptamer in vivo..  22:1423-1428. 2004
  • A simple method to cure established tumors by inflammatory killing of normal cells..  22:1125-1132. 2004
  • Alternative splicing in disease and therapy..  22:535-546. 2004
  • Mending the message..  21:1448-1449. 2003
  • Multicolor in vitro translation..  21:1093-1097. 2003
  • Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression..  20:587-591. 2002
  • Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing..  20:47-52. 2002
  • Training physicians for careers in clinical research: a tailored educational experience..  20:99-100. 2002
  • Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer..  19:342-347. 2001
  • Suppression of a P450 hydroxylase gene in plant trichome glands enhances natural-product-based aphid resistance..  19:371-374. 2001
  • Fingerprinting polysaccharides with single-molecule atomic force microscopy..  19:258-262. 2001
  • Antibody-based nanoprobe for measurement of a fluorescent analyte in a single cell..  18:764-767. 2000
  • The use of single-nucleotide polymorphism maps in pharmacogenomics..  18:505-508. 2000
  • High-fidelity mRNA amplification for gene profiling..  18:457-459. 2000
  • Purification of recombinant proteins by fusion with thermally-responsive polypeptides..  17:1112-1115. 1999
  • Noninvasive visualization of tumors in rodent dorsal skin window chambers..  17:1033-1035. 1999
  • Spliceosome-mediated RNA trans-splicing as a tool for gene therapy..  17:246-252. 1999
  • Erratum: Spliceosome-mediated RNA trans-splicing as a tool for gene therapy (Nature Biotechnology).  17:602. 1999
  • Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA..  16:364-369. 1998
  • Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa..  15:965-970. 1997
  • Evaluating and enhancing ribozyme reaction efficiency in mammalian cells..  15:902-905. 1997
  • Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies..  15:41-45. 1997
  • Stress is good and bad for tumors.  15:722-723. 1997
  • G protein-coupled receptors and receptor kinases: from molecular biology to potential therapeutic applications..  14:283-286. 1996